Skip to main content
Erschienen in: Supportive Care in Cancer 9/2015

01.09.2015 | Original Article

Post-allogeneic Hematopoietic Stem Cell Transplantation (HSCT) changes in inorganic salivary components

verfasst von: C. C. Boer, M. E. P. Correa, L. M. A. Tenuta, C. A. Souza, A. C. Vigorito

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2015

Einloggen, um Zugang zu erhalten

Abstract

Recent studies have considered the qualitative and quantitative assessment of salivary flow, as well the biochemical components of saliva, as possible biomarkers that might contribute to the pathogenesis of chronic graft-versus-host disease (cGHVD) in hematopoietic stem cell transplantation (HSCT) patients. The aim of this study was to evaluate prospectively the inorganic salivary status at different periods of allogeneic HSCT. Saliva collection and oral examination were performed prior to the HSCT, ​between days 8 and 10, days 80 and 100, and at the cGVHD onset. Concentrations of calcium (Ca), phosphate (Pi), chloride (Cl), magnesium (Mg), potassium (K), and sodium (Na) were performed using colorimetric reactions and atomic absorption. Fifty-five consecutive patients undergoing first allogeneic HSCT were included in this study. Between days 8 and 10, the salivary flow rate was significantly higher (p = 0.05), Pi concentration was decreased (p = 0.007), and Na and Cl were increased (p = 0.001 and p = 0.001, respectively), compared with the baseline. Salivary flow rate during the same period showed a negative correlation with Pi concentration (p = 0.02) and a positive correlation with Na and Cl concentrations (p = 0.003 and p = 0.001, respectively). The salivary flow rate was decreased between days 80 and 100 (p = 0.02) and Na, Cl, and K concentrations were increased (p = 0.03, p = 0.02, and p = 0.003, respectively). Salivary flow rate showed a negative correlation with Na and Cl (p = 0.01 and p = 0.013, respectively). At cGVHD onset, the salivary flow rate showed no statistical difference compared with the other studied periods. A trend was observed in the higher Na concentration compared with the baseline (p = 0.06) and Pi concentration presented a significant decrease (p = 0.004). Ca and Mg concentrations showed no changes during all evaluation periods. The present study showed changes in inorganic salivary components in post-HSCT periods, mainly during the early period post-HSCT and at the cGVHD onset. We speculate that Na, Cl, and Pi in saliva could be used as a potential biomarker in further studies.
Literatur
1.
Zurück zum Zitat Dens F, Boogaerts M, Boute P, Declerck D, Demuynck H, Vinckier F (1996) Quantitative determination of immunological components of salivary gland secretion in transplant recipients. Bone Marrow Transplant 17(3):421–423PubMed Dens F, Boogaerts M, Boute P, Declerck D, Demuynck H, Vinckier F (1996) Quantitative determination of immunological components of salivary gland secretion in transplant recipients. Bone Marrow Transplant 17(3):421–423PubMed
3.
Zurück zum Zitat Nagler RM, Nagler A (2003) Sialometrical and sialochemical analysis of patients with chronic graft-versus-host disease—a prolonged study. Cancer Invest 21(1):34–40PubMedCrossRef Nagler RM, Nagler A (2003) Sialometrical and sialochemical analysis of patients with chronic graft-versus-host disease—a prolonged study. Cancer Invest 21(1):34–40PubMedCrossRef
4.
Zurück zum Zitat Coracin FL, Pizzigatti Correa ME, Camargo EE et al (2006) Major salivary gland damage in allogeneic hematopoietic progenitor cell transplantation assessed by scintigraphic methods. Bone Marrow Transplant 37(10):955–959. doi:10.1038/sj.bmt.1705351 PubMedCrossRef Coracin FL, Pizzigatti Correa ME, Camargo EE et al (2006) Major salivary gland damage in allogeneic hematopoietic progenitor cell transplantation assessed by scintigraphic methods. Bone Marrow Transplant 37(10):955–959. doi:10.​1038/​sj.​bmt.​1705351 PubMedCrossRef
6.
Zurück zum Zitat Chaushu GG, Itzkovitz-Chaushu SS, Yefenof EE, Slavin SS, Or RR, Garfunkel AAA (1995) A longitudinal follow-up of salivary secretion in bone marrow transplant patients. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endodontol 79(2):6–6. doi:10.1016/S1079-2104(05)80276-8 CrossRef Chaushu GG, Itzkovitz-Chaushu SS, Yefenof EE, Slavin SS, Or RR, Garfunkel AAA (1995) A longitudinal follow-up of salivary secretion in bone marrow transplant patients. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endodontol 79(2):6–6. doi:10.​1016/​S1079-2104(05)80276-8 CrossRef
7.
Zurück zum Zitat Filipovich AH, Weisdorf D, Pavletic S et al (2005) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 11(12):945–956. doi:10.1016/j.bbmt.2005.09.004 PubMedCrossRef Filipovich AH, Weisdorf D, Pavletic S et al (2005) National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 11(12):945–956. doi:10.​1016/​j.​bbmt.​2005.​09.​004 PubMedCrossRef
9.
Zurück zum Zitat Petersen PE. The World Oral Health Report 2003: continuous improvement of oral health in the 21st century—the approach of the WHO Global Oral Health Programme. Community Dentistry and oral epidemiology. 2003. Petersen PE. The World Oral Health Report 2003: continuous improvement of oral health in the 21st century—the approach of the WHO Global Oral Health Programme. Community Dentistry and oral epidemiology. 2003.
12.
Zurück zum Zitat Sreebny LM, Xerostomia VA (1988) Part I: relationship to other oral symptoms and salivary gland hypofunction. Oral Surg Oral Med Oral Pathol 66(4):451–458PubMedCrossRef Sreebny LM, Xerostomia VA (1988) Part I: relationship to other oral symptoms and salivary gland hypofunction. Oral Surg Oral Med Oral Pathol 66(4):451–458PubMedCrossRef
14.
Zurück zum Zitat Sonis ST, Oster G, Fuchs H et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19(8):2201–2205PubMed Sonis ST, Oster G, Fuchs H et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19(8):2201–2205PubMed
15.
Zurück zum Zitat Yamagata K, Arai C, Sasaki H et al (2011) The effect of oral management on the severity of oral mucositis during hematopoietic. SCT 47(5):725–730. doi:10.1038/bmt.2011.171 Yamagata K, Arai C, Sasaki H et al (2011) The effect of oral management on the severity of oral mucositis during hematopoietic. SCT 47(5):725–730. doi:10.​1038/​bmt.​2011.​171
16.
17.
Zurück zum Zitat Izutsu KT, Sullivan KM, Schubert MM et al (1983) Disordered salivary immunoglobulin secretion and sodium transport in human chronic graft-versus-host disease. Transplantation 35(5):441PubMedCrossRef Izutsu KT, Sullivan KM, Schubert MM et al (1983) Disordered salivary immunoglobulin secretion and sodium transport in human chronic graft-versus-host disease. Transplantation 35(5):441PubMedCrossRef
18.
Zurück zum Zitat Imanguli MM, Pavletic SZ, Guadagnini J-P, Brahim JS, Atkinson JC (2006) Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endodontol 101(2):9–9. doi:10.1016/j.tripleo.2005.08.028 CrossRef Imanguli MM, Pavletic SZ, Guadagnini J-P, Brahim JS, Atkinson JC (2006) Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endodontol 101(2):9–9. doi:10.​1016/​j.​tripleo.​2005.​08.​028 CrossRef
20.
Zurück zum Zitat Tanaka M (2002) Secretory function of the salivary gland in patients with taste disorders or xerostomia: correlation with zinc deficiency. Acta Otolaryngol 122(4):134–141CrossRef Tanaka M (2002) Secretory function of the salivary gland in patients with taste disorders or xerostomia: correlation with zinc deficiency. Acta Otolaryngol 122(4):134–141CrossRef
23.
Zurück zum Zitat Alborghetti MR, Corrêa M, Adam RL et al (2005) Late effects of chronic graft‐vs.‐host disease in minor salivary glands. J Oral Pathol Med 34(8):486–493PubMedCrossRef Alborghetti MR, Corrêa M, Adam RL et al (2005) Late effects of chronic graft‐vs.‐host disease in minor salivary glands. J Oral Pathol Med 34(8):486–493PubMedCrossRef
25.
Zurück zum Zitat Del Vigna PV, de Almeida P, Grégio AMTA, Machado MANM, de Lima AASA, Azevedo LRL (2008) Saliva composition and functions: a comprehensive review. Audio Trans IRE Prof Group on 9(3):72–80 Del Vigna PV, de Almeida P, Grégio AMTA, Machado MANM, de Lima AASA, Azevedo LRL (2008) Saliva composition and functions: a comprehensive review. Audio Trans IRE Prof Group on 9(3):72–80
Metadaten
Titel
Post-allogeneic Hematopoietic Stem Cell Transplantation (HSCT) changes in inorganic salivary components
verfasst von
C. C. Boer
M. E. P. Correa
L. M. A. Tenuta
C. A. Souza
A. C. Vigorito
Publikationsdatum
01.09.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2015
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-015-2613-0

Weitere Artikel der Ausgabe 9/2015

Supportive Care in Cancer 9/2015 Zur Ausgabe

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.